权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

基本信息

批准号：
10337032
负责人：
Maurizio Del Poeta
金额：
--
依托单位：
NORTHPORT VA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-10-01 至 2025-09-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10337032
关键词：
Acquired Immunodeficiency Syndrome Adrenal Cortex Hormones Animal Model Antifungal Agents Antifungal Therapy Aspergillus fumigatus Autoimmune Diseases Award Biological Assay Brain CD4 Positive T Lymphocytes Candida albicans Cell Count Cells Ceramides Cessation of life Clinic Clinical Collaborations Communicable Diseases Communities Containment Cryptococcal Meningitis Cryptococcosis Cryptococcus Cryptococcus neoformans Dependence Development Disease Drug Design Drug Formulations Drug resistance Educational process of instructing Effectiveness Ensure Environment Enzymes Exposure to Faculty Fungal Vaccines General Population Glucosylceramides Goals Granuloma Growth HIV Hand Host Defense Immune Evasion Immune system Immunity Immunocompromised Host Industry Infection Injections Inositol Integration Host Factors Intervention Investigation Knowledge Laboratories Lead Lipids Lung Malignant Neoplasms Mediating Medical Medical center Molecular Morbidity - disease rate Mycoses Organ Transplantation Organism Pathogenesis Pathogenicity Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Physicians Population Postdoctoral Fellow Preventive Process Research Research Personnel Resistance SPHK1 enzyme Scientist Services Source South Carolina Specificity Sphingolipids Sphingomyelins Spinal Cord Structure Students Substance abuse problem Symptoms Technology Testing The science of Mycology Therapeutic Therapeutic immunosuppression Toxic effect Toxicology Training Universities Veterans Virulence Work alkalinity base career cross reactivity design experience fungus high throughput screening immunoregulation inhibitor interest microbial microorganism interaction military service mortality multiple sclerosis treatment novel novel therapeutic intervention novel therapeutics opportunistic pathogen patient population research and development small molecule sphingomyelin synthase sphingosine 1-phosphate therapeutically effective treatment strategy

项目摘要

ABSTRACT I am an Infectious Diseases physician-scientist with over 28 years of experience in medical mycology. During my career, I have been working in the clinic and at the bench, teaching and training many students, post-docs and junior faculty at Duke University, the Medical University of South Carolina, and now at Stony Brook University and at the Northport VA Medical Center. My overall career goal is to bring a new antifungal in the clinic, and I am closer than ever with MicroRid Technologies Inc., a start-up company I co-founded for the research and development of new antifungal drugs. My laboratory pioneered the studies on lipid-mediated infectious diseases. My lab and my co-workers reached such a high visibility in this field that we are continuously contacted for consultant work by investigators from all over the world for lipid analysis in their favorite organisms. My studies have mostly focused on fungal infections, particularly invasive fungal infections, because they are on the rise in our Veterans and in our non-Veterans populations. As we live longer thanks to many benefits of chemo- and immunosuppressive-therapies and organ transplantations, we are also facing a rise of invasive fungal infectious diseases. Current antifungals are either fungistatic, toxic, with narrow spectrum of activity or they become resistant. New treatment strategies are needed. In addition to develop a new class of antifungal agents, the studies in my laboratory are also crucial to the understanding of the host mechanisms required for fungal containment versus fungal dissemination and disease. For these studies, I partnered with many collaborators at the VA medical centers, at various Universities, and at the industry setting, establishing fruitful and successful collaborations. The VA RCS award will allow our group to continue this great work and will provide stability to fulfill the current goals and to start new research directions. The RCS Award will also allow me to broaden my collaborative research even further, particularly with the VA physicians involved in the MVP, enhancing my research clinical enterprise, and to continue my service to the scientific community at the VA and beyond.

抽象的我是一名传染病医师兼科学家，在医学真菌学领域拥有超过 28 年的经验。在我的职业生涯中，我一直在诊所和工作台工作，教学和培训许多人杜克大学、南卡罗来纳医科大学的学生、博士后和初级教师，现在在石溪大学和诺斯波特退伍军人医疗中心。我的总体职业目标是将一种新的抗真菌药物引入临床，我比以往任何时候都更接近 MicroRid Technologies Inc.，这是一家我与他人共同创立的一家初创公司，致力于新型抗真菌药物的研发。我的实验室开创了脂质介导的传染病的研究。我的实验室和我的同事在该领域达到了如此高的知名度，以至于我们不断地与我们联系以获得顾问工作来自世界各地的研究人员对他们最喜欢的生物体进行脂质分析。我的学业有主要关注真菌感染，特别是侵袭性真菌感染，因为它们位于我们的退伍军人和非退伍军人人口的增加。由于许多好处，我们寿命更长化疗和免疫抑制疗法以及器官移植，我们也面临着越来越多的侵袭性真菌感染性疾病。目前的抗真菌药物要么是抑制真菌的，要么是有毒的，并且作用范围很窄。活动范围，否则它们会产生耐药性。需要新的治疗策略。此外开发一类新型抗真菌药物，我实验室的研究对于了解真菌遏制与真菌传播所需的宿主机制和疾病。对于这些研究，我与退伍军人管理局医疗中心的许多合作者合作，各大学和行业环境建立了富有成效和成功的合作。这 VA RCS 奖项将使我们的团队能够继续这项伟大的工作，并将提供稳定性来实现当前的目标并开始新的研究方向。 RCS 奖还将让我拓宽我的视野进一步合作研究，特别是与参与 MVP 的 VA 医生，加强我的研究临床事业，并继续为科学界提供服务弗吉尼亚州及其他地区。